Company Filing History:
2 out of 441 
1 out of 50 
Years Active: 2016-2022
Title: Kenji Hirotani - Innovator in Tumor Treatment
Introduction
Kenji Hirotani is a prominent inventor based in Tokyo, Japan, known for his significant contributions to the field of cancer treatment. He holds two patents that focus on innovative methods for selecting candidates for immune checkpoint inhibitors and developing antibodies with antitumor activity.
Latest Patents
Hirotani's latest patents include a method for selecting individuals to be administered immune checkpoint inhibitors. This method involves collecting tumor tissue from the individual, determining the extent of B7-H3 expression in the collected tissue, and selecting the individual as a candidate for treatment if the B7-H3 expression level is considered negative. His second patent is for an anti B7-H3 antibody, which exhibits antitumor activity by binding to B7-H3. This patent also covers a pharmaceutical composition that includes the antibody, methods for making the antibody, and methods for treating tumors using the antibody.
Career Highlights
Throughout his career, Kenji Hirotani has worked with notable organizations, including Daiichi Sankyo Company, Limited and Kinki University. His work has significantly advanced the understanding and treatment of tumors, particularly through the development of immune checkpoint inhibitors.
Collaborations
Hirotani has collaborated with esteemed colleagues such as Shu Takahashi and Tatsuji Matsuoka. These collaborations have fostered innovation and contributed to the